Analysis: Himadri Speciality Chemical Limited

Growth thesis

Himadri Speciality Chemical is an operating-leverage story built on converting coal tar into higher-value carbon products at its integrated Mahistikry complex. The base is 600,000 MTPA of coal tar distillation, feeding coal tar pitch, speciality carbon black, naphthalene derivatives and forward-integrated chemicals. The company is now layering battery materials on top: LFP cathode active material, anode active material and silicon-carbon technology. The investment question is whether the new capacity converts into the guided INR1,100-plus crore FY28 PAT without breaking the per-tonne economics or the internal-accrual funding model.

Q2 FY27 showed the base business earning through a volatile raw-material and freight environment. Consolidated revenue was INR1,691 crore, EBITDA INR303 crore and PAT INR231 crore; H1 FY27 revenue was INR3,123 crore, EBITDA INR616 crore and PAT INR460 crore. Standalone Q2 revenue was INR1,543 crore, EBITDA INR308 crore and PAT INR240 crore. EBITDA per tonne was about INR20,990 versus INR17,910 a year earlier, though down INR1,500–1,800 sequentially. Management guided INR20,000–24,000 per tonne, with one answer at INR25,000, and argued that percentage margin is less meaningful because raw-material pass-through and freight move revenue. That is a credible operating frame for a converter, and the 88% carbon black utilisation with an 88–95% outlook supports it. But the gross margin still contracted about 500 bps year on year on pass-through timing and higher export freight, so the per-tonne range is not a guarantee.

The earnings path has three layers. First, the base business compounds from higher carbon black and coal tar pitch volumes and mix. Second, speciality projects commission: the full 5,300 MTPA anthraquinone and carbazole plant in Q4 FY27, the 2,000 MTPA LFP line in Q3 FY27, the 40,000 MTPA LFP plant by FY28 end, 200 MTPA CNT in Q4 FY27 and 6,000 MTPA super speciality carbon black in Q4 FY28. Third, Birla Tyres and mining can add incremental earnings. Management reaffirmed the INR1,100-plus crore FY28 PAT target, which H1 FY27 PAT of INR460 crore partially de-risks. The target is still guidance, not an achieved result, and it needs the new projects to ramp inside the window.

The most important near-term project is anthraquinone and carbazole. Management changed from a phased 2,600 MTPA in Q2 FY27 plus 2,700 MTPA in Q2 FY28 to commissioning the full 5,300 MTPA together in Q4 FY27. The reason is operational: avoiding a three-month shutdown to connect Phase 2. Trial runs are indicated for Q1 FY28, with nine months of full operation in FY28. At full capacity, prior guidance was INR250–300 crore top line. That is a high-value use of existing distillates and a clearer near-term revenue lever than LFP, but the first phase has slipped from Q2 to Q4 FY27.

LFP is the larger option and the larger execution risk. The 2,000 MTPA line remains targeted for Q3 FY27 and is designed to run sample B, C and D approvals on commercial-grade material. The 40,000 MTPA plant is now targeted for commissioning by FY28 end, with first-year utilisation above 50% and 90%+ the following year. At full capacity, management guides about INR3,000 crore top line on INR1,125 crore capex and a 2x asset turn. The call also contains an ambiguous reference to LFP commencing in FY29, so the exact commercial start is not clean. Customer approvals take 1.5–2 years, and Chinese incumbents hold most global LFP capacity. The IBC relationship is useful validation but not committed offtake: management clarified that IBC is a technology and EPC partner, not a material consumer, and Himadri material qualifies in cells built using IBC technology.

Anode is earlier. The 200 MTPA plant commissioned in April 2026, built on in-house engineered pitch, and sample B has been supplied to Indian and global customers. The theoretical revenue at full utilisation is only INR120–130 crore, and no commercial revenue was claimed in Q2 FY27. No large anode capacity or capex has been announced. Silicon-carbon capex is at an advanced engineering stage. Sicona's Advano acquisition and AUD45 million ARENA funding add technical depth, but not near-term volume. Anode is a technology option, not yet an earnings leg.

Birla Tyres has moved from restart to scaling. Q2 FY27 trading sales were INR140 crore with about INR1 crore trading margin, and management said breakeven was on track. The board has proposed a demerger of the tyre business from Dalmia Bharat Refractory into Himadri, subject to statutory, regulatory, creditor and shareholder approvals. The four-to-five-year INR3,000 crore top-line target is unchanged, and PCR is targeted by FY28 for EV and SUV tyres. The near-term evidence is still thin margin on trading sales; the merger and breakeven are open. Mining is a smaller swing factor: environmental clearance was received in October 2026, operations are targeted for the current quarter and management sees around INR500 crore top line on a broader basis, but no volume or margin schedule was given.

Capital allocation is the constraint that makes the thesis work or fail. FY27 capex is guided at INR800–900 crore, with more than INR400 crore already spent in H1. The Q&A refers to a INR1,500 crore project pool over two years, while the earlier aggregate was about INR2,000 crore including Birla Tyres. Management reiterated internal-accrual funding and no incremental debt. Working capital was 37% of sales at Q2 versus 41% in Q1, and receivables were 65 days. An analyst cited about INR500 crore net debt; management did not confirm the figure. The 30% ROCE hurdle remains the stated filter. If cash conversion slips, capex timing or the no-debt promise is tested.

The falsifiers are specific. First, the 2,000 MTPA LFP line must commission in Q3 FY27 and the 40,000 MTPA plant must be commissioned by FY28 end with a clear path to above 50% first-year utilisation; another slip would push the LFP earnings contribution out. Second, the full 5,300 MTPA anthraquinone and carbazole plant must commission in Q4 FY27 and run at full capacity for nine months in FY28. Third, Birla Tyres must move from thin trading margin to breakeven and the merger must clear approvals. Fourth, mining must ramp. Fifth, working capital must normalise so the INR800–900 crore FY27 capex is funded from internal accruals. If these fail, the INR1,100-plus crore FY28 PAT target compresses toward the base business, and the operating-leverage thesis loses its incremental earnings leg.

Why is Himadri Speciality Chemical Limited stock rising?

• Management reaffirmed the previously guided INR1,100+ crore consolidated PAT by FY28. H1 FY27 consolidated PAT was INR460 crore, so the target no longer starts from a zero base. It still depends on new capacity commissioning and ramp, particularly anthraquinone and LFP. The base business is already generating the earnings; the new projects are the increment.
• The full 5,300 MTPA plant is targeted for commissioning together in Q4 FY27, replacing the earlier phased plan. Management avoids a three-month shutdown to connect Phase 2 and expects nine months of full operation in FY28 after Q1 FY28 trials. At full capacity, prior guidance was INR250–300 crore top line. This is a near-term, high-value use of existing coal tar distillates.
• The first 2,000 MTPA LFP line is targeted for Q3 FY27, allowing sample B, C and D approvals to run on commercial-grade material. The 40,000 MTPA plant is targeted for commissioning by FY28 end, with first-year utilisation above 50% and 90%+ the following year. At full capacity, management guides about INR3,000 crore top line on INR1,125 crore capex. The call contains an ambiguous FY29 reference, so the ramp is not cleanly dated.
• Q2 FY27 carbon black utilisation was 88%, with management looking at 88–95% going forward. The 70,000 MT expansion is already commissioned, taking total carbon black capacity to 250,000 MTPA and speciality to 130,000 MTPA. The profit mechanism is mix and per-tonne spread, not volume alone. Q2 revenue growth included about 11% volume growth and higher raw-material and finished-product values.
• Q2 FY27 EBITDA per tonne was about INR20,990 versus INR17,910 a year earlier. Management guides INR20,000–24,000 per tonne and says percentage margin is less relevant because raw-material pass-through and freight move revenue. The sequential dip was attributed to pass-through timing and higher export freight, not a structural break. This per-tonne frame is the right way to test the base business.

Research report

companyname: Himadri Speciality Chemical Limited ticker: HSCL sector: Speciality Chemicals / Advanced Materials Himadri Speciality Chemical Limited (HSCL) was incorporated in 1987 in Kolkata as a coal tar derivatives company. Over nearly four decades it has moved up the carbon value chain into speciality chemicals and now battery materials. Management describes today's company as "a global advanced materials and application-driven solution organisation" positioned at the intersection of materia...

Catalysts

capex, margin expansion, new product segment

Growth guidance

Explicit forward guidance: consolidated PAT above INR1,100 crore by FY28; 200 MTPA CNT commissioning in Q4 FY27; 6,000 MTPA super speciality carbon black in Q4 FY28; 2,000 MTPA LFP in Q3 FY27 and 40,000 MTPA by FY28 end with first-year utilisation above 50% and 90%+ the next year; full 5,300 MTPA anthraquinone and carbazole in Q4 FY27; FY27 capex of INR800–900 crore; EBITDA per tonne of INR20,000–24,000, with one answer at INR25,000; carbon black utilisation of 88–95%; mining operational in the current quarter with around INR500 crore top line on a broader basis. No FY27 revenue or PAT guidance was given.

Management consistency

overdeliver